Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $223.7 million.

  • Vanda Pharmaceuticals' Short-term Investments fell 1886.9% to $223.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.7 million, marking a year-over-year decrease of 1886.9%. This contributed to the annual value of $272.3 million for FY2024, which is 787.66% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Short-term Investments stood at $223.7 million, which was down 1886.9% from $244.6 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Short-term Investments ranged from a high of $405.4 million in Q3 2022 and a low of $147.3 million during Q1 2023
  • Over the past 5 years, Vanda Pharmaceuticals' median Short-term Investments value was $306.0 million (recorded in 2021), while the average stood at $300.8 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 5999.31% in 2023, then soared by 8257.87% in 2024.
  • Vanda Pharmaceuticals' Short-term Investments (Quarter) stood at $380.7 million in 2021, then fell by 12.85% to $331.8 million in 2022, then fell by 23.92% to $252.4 million in 2023, then rose by 7.88% to $272.3 million in 2024, then dropped by 17.85% to $223.7 million in 2025.
  • Its Short-term Investments stands at $223.7 million for Q3 2025, versus $244.6 million for Q2 2025 and $229.1 million for Q1 2025.